Dr. Lowell L. Hart, MD

Dr. Hart practices at Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina.

Dr. Hart's NPI, 1245221993, was assigned on November 2, 2005. Dr. Hart graduated from SUNY Upstate Medical University in 1980. Dr. Hart holds Florida license ME39180.

Dr. Hart's primary practice is Davie Surgery - Ophthalmology - HOPD, at 329 Nc Highway 801 N, Bermuda Run, NC 27006.

Dr. Hart's primary practice is Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina. Dr. Hart is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Wake Forest Baptist. Dmand AI also links Dr. Hart to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hart practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Hart's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hart is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Hart's licenses on file in 2 states: Florida and North Carolina.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Hart treats.

CMS data shows 58,598 Medicare services from Dr. Hart across 44 procedure codes in 2024, for 853 Medicare patients. Medicare paid $1,130,809 for them.

CMS counts 853 Medicare patients who saw Dr. Hart in 2024. The largest group is 75 to 84, with 384 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hart's median patient age at 68, with 67% women.

In 2024, Dr. Hart wrote 1,900 Medicare Part D claims for 358 patients. 68% of them were for generic drugs. CMS names the drug for 1,642 of them, across 39 drugs with 11 or more claims each, at $5,151,258 in total drug cost. In 2023, CMS named 1,358 claims across 34 drugs.

Dr. Hart accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 86 papers to Dr. Hart, published from 2006 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and Receptor, ErbB-2. Dr. Hart has published most often in J Clin Oncol. Dr. Hart's most frequent co-authors are Howard A. Burris, MD, Ian Elliott Krop, MD, PhD and Sara Michell Tolaney, MD.

Dmand AI links Dr. Hart to 22 clinical trials, 6 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Neoplasm Metastasis. Eli Lilly and Company sponsors the most, 5. Open Payments lists research payments to Dr. Hart that name 5 trials.

CMS Open Payments shows 2,250 general payments to Dr. Hart from 100 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Eli Lilly and Company paid the most, $135,491. It also lists 26 research payments totaling $40,107 from 2016 to 2025, naming 5 clinical trials.

Dmand AI lists 4 awards for Dr. Hart, most recently CMS Stage 1 EHR in 2014.

Dr. Hart graduated from SUNY Upstate Medical University in 1980. Dr. Hart is a member of ASCO.

Dr. Hart is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.